Abstract
The mevalonate pathway has become an important target for anti-cancer therapy. Manipulation of this pathway results in alteration of malignant cell growth and survival in cell culture and animal models, with promising potential for application in human cancers. Mevalonate is synthesized from 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA). Mevalonate is further metabolized to farnesyl pyrophosphate (FPP), which is the precursor for sterols. In addition, the farnesyl moiety from FPP is utilized for post-translational modification of proteins including small GTPases, such as Ras and Ras related proteins, which play a role in malignant transformation of cells. FPP is a precursor for geranylgeranyl pyrophosphate (GGPP), which is similarly involved in post-translational modification of proteins. There has been intense interest in manipulating the pathway through HMG-CoA reductase inhibition. More recently, the focus has been on manipulating the pathway by post-translational modification of key regulatory proteins through farnesyl prenyl transferase (FPTase) or geranylgeranyl prenyl transferase (GGPTase) inhibition. This review focuses on the mevalonate pathway and the application of rational drug therapies to manipulate this pathway. Included in the review are a summary of agents demonstrating success in preclinical investigations such as; farnesyl transferase inhibitors, geranylgeranyl transferase inhibitors, dual inhibitors, statins, bisphosphonates, histone deacetylase inhibitors and other compounds. While these agents have shown preclinical success, translation to success in clinical trials has been more difficult. These clinical trials are reviewed along with evaluation of some of the potential problems with these agents in their clinical application.
Keywords: Mevalonate pathway, isoprenoids, cancer therapy, FPTase, Ras proteins
Current Cancer Drug Targets
Title: Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Volume: 6 Issue: 1
Author(s): Kelly M. Swanson and Raymond J. Hohl
Affiliation:
Keywords: Mevalonate pathway, isoprenoids, cancer therapy, FPTase, Ras proteins
Abstract: The mevalonate pathway has become an important target for anti-cancer therapy. Manipulation of this pathway results in alteration of malignant cell growth and survival in cell culture and animal models, with promising potential for application in human cancers. Mevalonate is synthesized from 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA). Mevalonate is further metabolized to farnesyl pyrophosphate (FPP), which is the precursor for sterols. In addition, the farnesyl moiety from FPP is utilized for post-translational modification of proteins including small GTPases, such as Ras and Ras related proteins, which play a role in malignant transformation of cells. FPP is a precursor for geranylgeranyl pyrophosphate (GGPP), which is similarly involved in post-translational modification of proteins. There has been intense interest in manipulating the pathway through HMG-CoA reductase inhibition. More recently, the focus has been on manipulating the pathway by post-translational modification of key regulatory proteins through farnesyl prenyl transferase (FPTase) or geranylgeranyl prenyl transferase (GGPTase) inhibition. This review focuses on the mevalonate pathway and the application of rational drug therapies to manipulate this pathway. Included in the review are a summary of agents demonstrating success in preclinical investigations such as; farnesyl transferase inhibitors, geranylgeranyl transferase inhibitors, dual inhibitors, statins, bisphosphonates, histone deacetylase inhibitors and other compounds. While these agents have shown preclinical success, translation to success in clinical trials has been more difficult. These clinical trials are reviewed along with evaluation of some of the potential problems with these agents in their clinical application.
Export Options
About this article
Cite this article as:
Swanson M. Kelly and Hohl J. Raymond, Anti-Cancer Therapy: Targeting the Mevalonate Pathway, Current Cancer Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/156800906775471743
DOI https://dx.doi.org/10.2174/156800906775471743 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Evaluation of Tricine and EDDA as Co-ligands for <sup>99m</sup>Tc-Labeled HYNIC-MSH Analogs for Melanoma Imaging
Anti-Cancer Agents in Medicinal Chemistry Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients
Current Proteomics Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry The Application of Optical Technology in Microfluidic Systems
Current Proteomics Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Analgesic Effects and Assays of Controlled-Release Tramadol and O-Desmethyltramadol in Cancer Patients with Pain
Current Pharmaceutical Biotechnology An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Diabetes Mellitus as a Risk Factor for Cancer: Stress or Viral Etiology?
Infectious Disorders - Drug Targets DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Inhibition of Carbonic Anhydrase IX: A New Strategy Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery